STOCK TITAN

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has announced its participation in the BIO-Europe Partnering Conference taking place from October 24-26, 2022, in Lepzing, Germany. The company's VP of Business Development, Nedira Salzman Frenkel, will engage with potential partners in the CNS space to explore collaboration opportunities. Concurrently, Dr. Niva Russek Blum, VP Discovery & IP Generator, will assess assets from various institutions focusing on neurological conditions. NeuroSense is dedicated to developing therapies for severe neurodegenerative diseases, such as ALS and Alzheimer's.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass, Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in Lepzing, Germany.

NeuroSense Therapeutics Logo

 

NeuroSense's VP Business Development, Nedira Salzman Frenkel, will meet with companies in the CNS field to explore potential collaboration and partnership opportunities, and Dr. Niva Russek Blum, VP Discovery & IP Generator will evaluate assets from institutions and companies working on neurology indications.

Prospective partners and interested parties attending BIO-Europe may request a meeting with NeuroSense by emailing: pbz@neurosense-tx.com 

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding participating in conferences; the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

 

 

Cision View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-to-participate-in-bio-europe-partnering-conference-on-october-24-26-2022-in-lepzing-germany-301656060.html

SOURCE NeuroSense

FAQ

What event is NeuroSense participating in on October 24-26, 2022?

NeuroSense is participating in the BIO-Europe Partnering Conference in Lepzing, Germany.

Who will represent NeuroSense at the BIO-Europe Conference?

Nedira Salzman Frenkel, VP of Business Development, will represent NeuroSense.

What is the focus of NeuroSense's collaborations at the conference?

NeuroSense aims to explore partnerships in the CNS field.

What does NeuroSense Therapeutics develop?

NeuroSense develops treatments for severe neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's.

How can potential partners contact NeuroSense during the conference?

Interested parties can request meetings by emailing pbz@neurosense-tx.com.

NeuroSense Therapeutics Ltd. Ordinary Shares

NASDAQ:NRSN

NRSN Rankings

NRSN Latest News

NRSN Stock Data

28.91M
15.87M
23.91%
1.09%
1.3%
Biotechnology
Healthcare
Link
United States of America
Herzliya